Get the Stockscreener App
6.425
0.85%
-0.055
Organon Co stock is traded at $6.425, with a volume of 522.48K.
It is down -0.85% in the last 24 hours and down -16.45% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$6.48
Open:
$6.45
24h Volume:
522.48K
Relative Volume:
0.10
Market Cap:
$1.67B
Revenue:
$6.22B
Net Income/Loss:
$187.00M
P/E Ratio:
8.966
EPS:
0.7166
Net Cash Flow:
$508.00M
1W Performance:
-6.48%
1M Performance:
-16.45%
6M Performance:
-39.73%
1Y Performance:
-58.81%
1-Day Range:
$6.38
$6.515
1-Week Range:
$6.34
$6.98
52-Week Range:
$6.18
$15.88
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.425 | 1.69B | 6.22B | 187.00M | 508.00M | 0.7166 |
|
LLY
Lilly Eli Co
|
997.70 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.41 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.51 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
194.26 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
156.07 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon trades in red for seven straight sessions - MSN
(OGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - Sahm
Organon rises after update on independent review - MSN
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Royce & Associates LP Trims Position in Organon & Co. $OGN - MarketBeat
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Organon (OGN) Pricing Reflect Its Value After Reported Sun Pharma Takeover Interest - Yahoo Finance
OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia
Assessing Organon (OGN) Valuation After VTAMA Sleep Outcome Data From Phase 3 ADORING Trials - simplywall.st
Organon presents sleep improvement data for VTAMA cream in children - Investing.com
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - Sahm
Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks
Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat
Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat
Organon price target raised to $8 from $7.50 at Barclays - TipRanks
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India
Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus - TechStock²
Organon Signs Deal for Global Rights to Sebela's Miudella Intrauterine Device - marketscreener.com
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals - Investing.com
Organon Licenses MIUDELLA® to Enhance Women's Health Commitment - Intellectia AI
Organon enters into agreement to license Miudella® - marketscreener.com
First hormone-free copper IUD in 40 years lands $27.5M Organon deal - Stock Titan
Organon (OGN) Is Up 9.6% After Weaker 2025 Earnings And New 2026 Revenue GuidanceWhat's Changed - simplywall.st
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon Shares Rally as Investigation Clears Company of Wrongdoing - AD HOC NEWS
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Up 6.6%What's Next? - MarketBeat
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):